RANK/RANK-L/OPG in Patients with Bone Metastases Treated with Anticancer Agents and Zoledronic Acid: A Prospective Study

Patients with solid cancer frequently develop bone metastases (BM). Zoledronic acid (Zometa(®), ZA), routinely used to treat patients with BM, acts on osteoclasts and also has antitumor properties. We aimed to assess the effect of ZA over time in novel bone turnover markers (RANK/receptor activator...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mercatali, Laura, Ricci, Marianna, Scarpi, Emanuela, Serra, Patrizia, Fabbri, Francesca, Ricci, Rossana, Liverani, Chiara, Zanoni, Michele, Zoli, Wainer, Maltoni, Roberta, Gunelli, Erica, Amadori, Dino, Ibrahim, Toni
Formato: Artigo
Idioma:Inglês
Publicado em: Molecular Diversity Preservation International (MDPI) 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3709696/
https://ncbi.nlm.nih.gov/pubmed/23702841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms140610683
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados